TTNP Stock Price, Titan Pharmaceuticals Quote, Chart

Market Summary

USD6.34-0.14

Market Closed

-2.16%

TTNP Stock Price

View Fullscreen

TTNP RSI Chart

TTNP Valuation

Market Cap

5.8M

Price/Earnings (Trailing)

-1.17

Price/Sales (Trailing)

31.5

Price/Free Cashflow

-1

TTNP Price/Sales (Trailing)

TTNP Profitability

Return on Equity

-81.39%

Return on Assets

-74.54%

Free Cashflow Yield

-100.2%

TTNP Fundamentals

TTNP Revenue

Revenue (TTM)

184.0K

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

TTNP Earnings

Earnings (TTM)

-5.0M

Earnings Growth (Yr)

36.72%

Earnings Growth (Qtr)

32.23%

Breaking Down TTNP Revenue

Last 7 days

-8.1%

Last 30 days

-10.7%

Last 90 days

-11.0%

Trailing 12 Months

-59.9%

How does TTNP drawdown profile look like?

TTNP Financial Health

Current Ratio

11.83

TTNP Investor Care

Shares Dilution (1Y)

21.77%

Diluted EPS (TTM)

-8.54

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	463.5K	396.5K	304.5K	184.0K
2022	1.0M	741.0K	572.0K	557.5K
2021	4.4M	3.6M	2.8M	1.5M
2020	2.8M	3.5M	3.6M	4.8M
2019	5.5M	4.3M	3.6M	2.6M
2018	1.2M	3.8M	4.8M	6.6M
2017	11.4M	7.6M	3.9M	215.0K
2016	0	15.8M	15.0M	15.1M
2015	3.6M	3.5M	2.6M	1.7M
2014	6.2M	4.9M	3.6M	3.6M
2013	11.0M	11.9M	12.8M	10.5M
2012	4.4M	5.1M	5.3M	7.1M
2011	8.9M	6.5M	5.3M	4.1M
2010	0	0	0	10.1M
2009	0	0	0	0
2008	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Titan Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 18, 2024	choong choon hau	acquired	-	-	54,132	-
Oct 25, 2023	ben-tzvi avraham	acquired	-	-	16,250	-
Oct 25, 2023	greenberg eric howard	acquired	-	-	16,250	-
Oct 25, 2023	mcmurdo matthew charles	acquired	-	-	16,250	-
Oct 25, 2023	beebe katherine	acquired	-	-	16,250	president and coo
Oct 25, 2023	natan david	acquired	-	-	16,250	-
Jul 26, 2023	chasey peter louis	acquired	-	-	50,000	-
Jul 26, 2023	ben-tzvi avraham	acquired	-	-	50,000	-
Jul 26, 2023	greenberg eric howard	acquired	-	-	50,000	-

Which funds bought or sold TTNP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	sold off	-100	-15,793	-	-%
May 15, 2024	MORGAN STANLEY	sold off	-100	-1.00	-	-%
May 15, 2024	MORGAN STANLEY	new	-	21.00	21.00	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-85.00	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	new	-	86.00	86.00	-%
May 15, 2024	Nemes Rush Group LLC	new	-	8.00	8.00	-%
May 15, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-638	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	new	-	4,633	4,633	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-6,234	-	-%
May 14, 2024	NewEdge Advisors, LLC	sold off	-100	-2.00	-	-%

Are Funds Buying or Selling TTNP?

Are funds buying TTNP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TTNP

No. of Funds

Unveiling Titan Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 05, 2024	sire group ltd.	14.1%	150,087	SC 13D/A
Oct 04, 2023	sire group ltd.	16.7%	3,001,757	SC 13D
Jul 21, 2023	choong choon hau	24.95%	3,747,968	SC 13D
Jun 23, 2023	activist investing llc	0%	0	SC 13D/A
Dec 15, 2022	activist investing llc	25.2%	3,690,468	SC 13D/A
Aug 17, 2022	activist investing llc	25.2%	3,690,468	SC 13D/A
Jul 08, 2022	activist investing llc	25.2%	3,690,468	SC 13D/A
Jun 09, 2022	activist investing llc	9.9%	1,441,278	SC 13D/A
Apr 25, 2022	activist investing llc	5.6%	673,211	SC 13D
Feb 14, 2022	l1 capital global opportunities master fund, ltd.	4.99%	494,716	SC 13G/A

Recent SEC filings of Titan Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
Apr 26, 2024	RW	RW
Apr 05, 2024	SC 13D/A	13D - Major Acquisition
Apr 05, 2024	3	Insider Trading
Apr 05, 2024	3	Insider Trading
Apr 03, 2024	8-K	Current Report
Apr 01, 2024	8-K	Current Report
Apr 01, 2024	10-K	Annual Report
Mar 27, 2024	4	Insider Trading
Mar 21, 2024	8-K	Current Report

Peers (Alternatives to Titan Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Titan Pharmaceuticals Inc News

Latest updates

Titan Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-	-	-	3.00	83.00	98.00	121	95.00	150	192	135	264	445	682	1,445	1,018	1,249	1,126	211	947	502	945
Costs and Expenses	-	-	-	2,471	1,671	1,795	-	2,738	2,592	2,731	2,624	2,172	2,770	3,314	3,901	2,214	2,867	3,101	-4,963	4,830	5,384	5,230
Operating Expenses	-	1,063	-	-	-	1,795	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,230
S&GA Expenses	-100.0%	-	1,038	2,047	1,229	1,234	1,289	1,806	1,618	1,322	1,648	979	1,035	1,327	1,856	1,327	1,223	1,289	-3,935	3,023	3,231	3,082
R&D Expenses	-100.0%	-	487	424	442	561	1,443	932	974	1,409	976	1,193	1,646	1,877	1,573	887	1,644	1,812	-290	1,619	1,907	1,844
Interest Expenses	-23.5%	13.00	17.00	-	-	-	-	-	-	-	-	-	-	-	-	97.00	96.00	102	104	109	110	109
Net Income	32.2%	-1,060	-1,564	-744	-1,586	-1,675	-2,566	-2,638	-2,462	-2,540	-2,540	-1,915	-1,680	-2,641	-3,085	-4,932	-4,641	-5,584	-3,941	-2,803	-5,197	-4,517
Net Income Margin	11.0%	-26.92*	-30.27*	-21.58*	-21.35*	-20.15*	-18.31*	-17.80*	-12.76*	-8.37*	-5.75*	-3.29*	-3.44*	-3.48*	-3.77*	-	-	-	-	-	-	-
Free Cashflow	66.5%	-618	-1,845	-2,246	-1,117	-1,904	-1,584	-1,878	-1,772	-2,969	-1,086	-2,262	-1,949	-2,625	-4,570	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-17.8%	6,646	8,086	9,999	812	2,168	4,058	6,276	8,319	10,318	7,994	9,637	11,507	13,824	8,087	8,018	9,762	13,262	9,522	5,304	6,761	11,440
Current Assets	-17.5%	6,611	8,018	9,899	498	1,785	3,603	5,747	7,713	9,633	7,229	8,845	10,630	13,189	7,328	6,649	8,690	12,146	8,308	3,946	5,493	10,089
Cash Equivalents	-8.9%	6,159	6,760	8,096	105	1,136	2,937	4,450	6,420	8,138	6,332	7,418	9,680	11,629	5,413	4,073	5,498	8,038	5,223	921	2,292	5,909
Inventory	-	-	-	-	-	106	106	460	469	293	293	129	129	218	328	1,073	969	1,064	563	1,309	1,317	1,246
Net PPE	-40.0%	3.00	5.00	6.00	9.00	181	224	269	317	368	420	468	524	563	618	1,161	799	780	817	752	754	782
Liabilities	-61.3%	559	1,444	1,866	1,846	2,480	2,695	2,726	2,652	2,436	2,856	2,141	2,760	3,844	4,555	8,915	8,202	7,986	8,089	7,964	7,332	8,385
Current Liabilities	-61.3%	559	1,444	1,866	1,846	2,447	2,630	2,630	2,524	2,278	2,669	1,925	2,516	3,756	4,223	5,877	4,857	4,410	3,600	3,482	4,342	4,761
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	88.00	332	3,038	3,345	3,500	4,019	3,872	2,698	3,242
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	572	327	2,082	1,624	667	-	-	1,333	1,227
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	88.00	332	3,038	3,345	3,500	4,019	3,872	2,698	3,242
Shareholder's Equity	-8.4%	6,087	6,642	8,133	-	-312	1,363	3,550	5,667	7,882	5,138	7,496	8,747	9,980	3,532	-	1,560	5,276	1,433	-	-	3,055
Retained Earnings	-0.3%	-392,890	-391,830	-390,266	-389,522	-387,936	-386,261	-383,695	-381,057	-378,595	-376,055	-373,515	-371,600	-369,920	-367,279	-364,194	-359,262	-354,621	-349,037	-345,096	-342,293	-337,096
Additional Paid-In Capital	0.1%	398,975	398,470	398,383	388,473	387,609	387,623	387,230	386,709	386,465	381,183	381,001	380,337	379,890	370,804	363,180	360,725	359,804	350,468	342,419	341,708	340,138
Shares Outstanding	17.0%	914	782	15,016	751	751	751	731	685	602	496	493	493	464	357	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	-	7,300	-	-	-	25,600	-	-	-	29,700	-	-	-	17,300	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	66.7%	-613	-1,840	-2,241	-1,112	-1,899	-1,579	-1,873	-1,767	-2,964	-1,081	-2,262	-1,931	-2,625	-4,561	-3,447	-3,983	-5,212	-3,663	-3,325	-4,149	-4,308
Share Based Compensation	-100.0%	-	48.00	411	264	290	-91.00	27,000	27.00	253	146	9.00	447	248	3.00	9.00	79.00	-84.00	-42.00	128	350	136
Cashflow From Investing	-100.0%	-	504	-	-	-	-	-	-	-	-5.00	-	-18.00	-	-9.00	-444	-57.00	-30.00	-112	-61.00	-39.00	-44.00
Cashflow From Financing	-	-	-	-	-	-	-	-	3.00	4,981	-	-	-	8,841	5,910	2,466	1,500	8,057	8,077	2,015	571	605

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TTNP Income Statement

2024-03-31

CONDENSED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenues		$ 98
Operating expenses:
Research and development		561
General and administrative	1,063	1,234
Total operating expenses	1,063	1,795
Loss from operations	(1,063)	(1,697)
Other income:
Interest income, net	1	22
Other income, net	2
Other income, net	3	22
Net loss	$ (1,060)	$ (1,675)
Basic net loss per common share	$ (1.24)	$ (2.23)
Diluted net loss per common share	$ (1.24)	$ (2.23)
Weighted average shares used in computing basic net loss per common share	853	751
Weighted average shares used in computing diluted net loss per common share	853	751
Grant [Member]
Revenues:
Total revenues		$ 98

TTNP Balance Sheet

2024-03-31

CONDENSED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 6,159	$ 6,760
Restricted cash		13
Receivables	134	46
Notes receivable		1,000
Prepaid expenses and other current assets	318	199
Total current assets	6,611	8,018
Property and equipment, net	3	5
Operating lease right-of-use asset, net	32	63
Total assets	6,646	8,086
Current liabilities:
Accounts payable	371	348
Note payable to related party		500
Other accrued liabilities	155	519
Operating lease liability, current	33	65
Deferred grant revenue		12
Total current liabilities	559	1,444
Total liabilities	559	1,444
Stockholders’ equity (deficit):
Preferred stock, at amounts paid in, $0.001 par value per share; 5,000,000 shares authorized, 950,000 shares issued and outstanding at March 31, 2024 and December 31, 2023.	1	1
Common stock, at amounts paid in, $0.001 par value per share; 225,000,000 shares authorized, 914,234 and 781,503 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively.	1	1
Additional paid-in capital	398,975	398,470
Accumulated deficit	(392,890)	(391,830)
Total stockholders’ equity	6,087	6,642
Total liabilities and stockholders’ equity	$ 6,646	$ 8,086

About Titan Pharmaceuticals Inc

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.

CEO	Mr. David Elliot Lazar
WEBSITE	titanpharm.com
INDUSTRY	Biotechnology
EMPLOYEES	4

Titan Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Titan Pharmaceuticals Inc? What does TTNP stand for in stocks?

TTNP is the stock ticker symbol of Titan Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Titan Pharmaceuticals Inc (TTNP)?

As of Fri May 17 2024, market cap of Titan Pharmaceuticals Inc is 5.8 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TTNP stock?

You can check TTNP's fair value in chart for subscribers.

What is the fair value of TTNP stock?

You can check TTNP's fair value in chart for subscribers. The fair value of Titan Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Titan Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TTNP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Titan Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether TTNP is over valued or under valued. Whether Titan Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Titan Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TTNP.

What is Titan Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, TTNP's PE ratio (Price to Earnings) is -1.17 and Price to Sales (PS) ratio is 31.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TTNP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Titan Pharmaceuticals Inc's stock?

In the past 10 years, Titan Pharmaceuticals Inc has provided -0.534 (multiply by 100 for percentage) rate of return.